# UK Medicines and Healthcare products Regulatory Agency (MHRA)

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/uk-medicines-and-healthcare-products-regulatory-agency-mhra
Canonical HTML page: https://gethealthbrief.com/entity/uk-medicines-and-healthcare-products-regulatory-agency-mhra

## Timeline

- **2026-02-20**: MHRA Suspension — The medicines regulator pauses the trial citing new concerns, halting the primary access route for patients.
- **2025-06-15**: Clinical Trial Launch — The UK government and NHS launch a formal clinical trial to gather long-term data on treatment outcomes.
- **2024-05-01**: NHS Routine Ban — NHS England ends the routine prescription of puberty blockers for gender dysphoria.
- **2024-04-10**: Cass Review Published — Final report recommends puberty blockers only be administered within a research setting due to lack of evidence.

## Recent coverage (1 stories)

### MHRA Pauses UK Puberty Blocker Trial Over Regulatory Concerns
2026-02-20 23:03:11 · Sentiment: Negative · Impact: 7/10 · Sources: 9

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has halted a major clinical trial into puberty blockers for minors following the emergence of new regulatory concerns. This suspension effectively closes the primary legal pathway for gender-distressed youth to access these treatments within the NHS framework.
Full story: https://gethealthbrief.com/story/uk-puberty-blocker-trial-paused-mhra

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.